BiomX Testing Potential Therapy for CF Lung Infections
BiomX has unveiled a platform designed for more rapid and efficient development of phage therapy, which the company is using to test...
Phase 3 ASPEN Trial Testing Brensocatib Now Recruiting; First Patient Dosed
The first participant has been dosed in ASPEN, a Phase 3 trial — now recruiting patients — that is evaluating the investigational...
Study Recommends Longer Rest Interval Between 6-min Walk Tests for Non-CF Bronchiectasis Patients
Two consecutive six-minute walk tests (6MWT) — which measure the distance a patient can walk in that time to assess their exercise...
Study Identifies Risk Factors of Malnutrition in Children With CF
Children with cystic fibrosis (CF) who are older, thinner, or have worse lung function may be at increased risk of malnutrition, a study...
Moscow Scientists Edge Closer To A Breakthrough For Cystic Fibrosis
Scientists at Moscow’s Bochkov Medical Genetic Research Center have successfully corrected a mutation of the CFTR gene, which causes...
Welcome to the team
MECFA welcomes Dr. Susanna A. McColley to our team to lead the MECFA Diagnostic Program. Susanna A. McColley, MD is Associate Chief...
Pegylation Provides Long‐acting Version of Dornase Alfa for CF Treatment
A modified version of Pulmozyme (dornase alfa), a widely-used cystic fibrosis (CF) therapy, lasts longer and reduces the need for...
A. fumigatus Lung Infections Linked to Age, Long-term Antibiotic Use
Adult age up to 50 and chronic antibiotic use seem to be the greatest risk factors for lung infection by the fungus Aspergillus fumigatus...
Trial of MS1819, Pancreatic Enzyme Therapy, May Add New Patient Arm
AzurRx BioPharma is requesting a new patient arm be added to its ongoing Phase 2b trial investigating MS1819 capsules as a treatment for...
Relizorb Use Supports Weight, Height Gains in Tube-fed Patients, Study Finds
Relizorb, Alcresta Therapeutics‘ pancreatic enzyme treatment, led to significant weight and height improvements among cystic fibrosis...
